Experienced in Non-Small Cell Lung Cancer (NSCLC)

Dr. Shirnett Williamson

Radiation Oncology
625 N 6th Street, 
Phoenix, AZ 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Experienced in Non-Small Cell Lung Cancer (NSCLC)
625 N 6th Street, 
Phoenix, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Shirnett Williamson is a Radiation Oncologist in Phoenix, Arizona. Dr. Williamson is rated as an Experienced provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). Her top areas of expertise are Posterior Fossa Tumor, Radiation Induced Meningioma, Meningioma, and Endometrial Cancer. Dr. Williamson is currently accepting new patients.

Her clinical research consists of co-authoring 1 peer reviewed article and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has participated in 1 clinical trial in the study of Non-Small Cell Lung Cancer (NSCLC).

Specialties
Radiation Oncology
Licenses
Radiology in AZ
Hospital Affiliations
Kingman Regional Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 1 Less Insurance Carrier -

Locations

Dignity Health Cancer Institute at St. Joseph's
625 N 6th Street, Phoenix, AZ 85004

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer
A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer
Enrollment Status: Recruiting
Publish Date: December 02, 2025
Intervention Type: Drug, Other
Study Phase: Phase 3
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Enrollment Status: Recruiting
Publish Date: May 25, 2025
Intervention Type: Procedure, Radiation
Study Phase: Phase 3
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Drug, Procedure, Radiation
Study Drug: Atezolizumab
Study Phase: Phase 3
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: November 10, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Temozolomide
Study Phase: Phase 2
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 20, 2025
Intervention Type: Drug, Procedure, Radiation, Other
Study Drug: Olaparib
Study Phase: Phase 2
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2023
Intervention Type: Radiation
Study Phase: Not Applicable
View 5 Less Clinical Trials

1 Total Publications

Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints.
Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints.
Journal: International journal of radiation oncology, biology, physics
Published: February 08, 2018
Similar Doctors
Distinguished in Non-Small Cell Lung Cancer (NSCLC)
Dr. Steven E. Schild
Radiation Oncology
Distinguished in Non-Small Cell Lung Cancer (NSCLC)
Dr. Steven E. Schild
Radiation Oncology
13400 E Shea Blvd, 
Scottsdale, AZ 
 (170.6 miles away)
480-301-8000
Languages Spoken:
English
See accepted insurances

Steven Schild is a Radiation Oncologist in Scottsdale, Arizona. Dr. Schild is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Prostate Cancer, Prostatectomy, and Tissue Biopsy.

Distinguished in Non-Small Cell Lung Cancer (NSCLC)
Dr. Chi Zhang
Radiation Oncology
Distinguished in Non-Small Cell Lung Cancer (NSCLC)
Dr. Chi Zhang
Radiation Oncology

Mayo Clinic Arizona

13400 E Shea Blvd, 
Scottsdale, AZ 
 (170.6 miles away)
480-301-8000
Languages Spoken:
English, American Sign Language
See accepted insurances
Accepting New Patients
Offers Telehealth

Chi Zhang is a Radiation Oncologist in Scottsdale, Arizona. Dr. Zhang is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Acoustic Neuroma, Schwannoma, EGFR Positive Lung Cancer, and Small Cell Lung Cancer (SCLC). Dr. Zhang is currently accepting new patients.

Advanced in Non-Small Cell Lung Cancer (NSCLC)
Dr. Lauren D. Stegman
Radiation Oncology
Advanced in Non-Small Cell Lung Cancer (NSCLC)
Dr. Lauren D. Stegman
Radiation Oncology

Arizona Digestive Health PC

4611 E Shea Blvd, Suite 120, 
Phoenix, AZ 
 (162.9 miles away)
623-547-2600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lauren Stegman is a Radiation Oncologist in Phoenix, Arizona. Dr. Stegman is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Familial Prostate Cancer, Prostate Cancer, Pleuropulmonary Blastoma, and Small Cell Lung Cancer (SCLC). Dr. Stegman is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Williamson's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 49 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile